Breaking News Instant updates and real-time market news.

RDY

Dr. Reddy's

$39.15

1.08 (2.84%)

, RHHBY

Roche

$0.00

(0.00%)

10:44
06/03/19
06/03
10:44
06/03/19
10:44

Dr. Reddy's announces re-launch of Zenatane in the U.S. market

Dr. Reddy's Laboratories (RDY) announced the re-launch of Zenatane, 10 mg, 20 mg, 30 mg and 40 mg, a therapeutic equivalent generic version of Accutane, approved by the U.S. Food and Drug Administration. The product is being launched with an approved Risk Evaluation and Mitigation Strategy Program. The Zenatane, 10 mg, 20 mg, 30 mg and 40 mg brand and generic had U.S. sales of approximately $525M MAT for the most recent twelve months ending in March 2019 according to IQVIA Health. Accutane is a trademark of Hoffman LaRoche (RHHBY).

RDY

Dr. Reddy's

$39.15

1.08 (2.84%)

RHHBY

Roche

$0.00

(0.00%)

  • 03

    Jun

  • 04

    Jun

  • 20

    Jun

  • 06

    Aug

  • 18

    Aug

  • 19

    Aug

  • 02

    Sep

  • 04

    Nov

RDY Dr. Reddy's
$39.15

1.08 (2.84%)

02/19/19
LYON
02/19/19
UPGRADE
LYON
Buy
Dr. Reddy's upgraded yesterday to Buy from Outperform at CLSA
02/20/19
LSCM
02/20/19
NO CHANGE
Target $17
LSCM
Buy
Aquestive Therapeutics price target raised to $17 from $14 at Lake Street
Lake Street analyst Thomas Flaten lowered his 2019 revenue estimate for Aquestive Therapeutics (AQST) to $43.5M from $67M after the Court of Appeals for the Federal Circuit issued its mandate yesterday, vacating the preliminary injunction that had barred Dr. Reddy's Laboratories (RDY) from entering the market. The analyst, however, believes any related downside has been more than priced into shares of Aquestive Therapeutics. He reiterates a Buy rating on the name and raised his price target for the stock to $17 from $14.
05/13/19
WELS
05/13/19
NO CHANGE
WELS
Lawsuit against Teva, others to hit generic drug stocks, says Wells Fargo
Wells Fargo analyst David Maris believes the lawsuit by 44 states against 20 generic drugmakers will weigh on generic drug stocks this week and remain an "overhang issue for some time." Actual penalties and damages are impossible to calculate, but could be material, Maris tells investors in a research note. The analyst spoke to the Connecticut attorney general's office this morning and learned they are preparing for trial in these cases. Language the attorney general has used, such as "unprecedented" and his desire to clawback all gains from collusion, should be indicative of the states' intent, Maris writes. He believes that for a sector that is generally highly levered, and with some companies named already facing an overhang from opioid litigation like Teva (TEVA), this is "especially unwelcome news."
05/20/19
MSCO
05/20/19
DOWNGRADE
MSCO
Equal Weight
Dr. Reddy's downgraded to Equal Weight from Overweight at Morgan Stanley
RHHBY Roche
$0.00

(0.00%)

04/22/19
BMOC
04/22/19
NO CHANGE
Target $96
BMOC
Outperform
Ionis Pharmaceuticals price target raised to $96 from $82 at BMO Capital
BMO Capital analyst Do Kim raised his price target on Ionis Pharmaceuticals (IONS) to $96 and kept his outperform rating after including the risk-adjusted royalties for HTT-Rx in his model as part of the update on its partnership with Roche (RHHBY) disclosed last month. The analyst notes that the stock price has started to reflect the company's Huntington's disease opportunity based on the "potential for an accelerated path with Phase 2 data" and believes that his HTT-Rx projections could prove to be "conservative".
05/09/19
LEHM
05/09/19
NO CHANGE
Target $245
LEHM
Equal Weight
Barclays cuts Biogen target to $245 on reduced Spinraza estimates
Barclays analyst Geoff Meacham lowered his price target for Biogen (BIIB) to $245 from $250 citing growing uncertainty in spinal muscular atrophy. Concerns over Spinraza in spinal muscular atrophy have intensified with the impending launch of Novartis' (NVS) gene therapy Zolgensma and Roche (RHHBY)/PTC's (PTCT) oral risdiplam, Meacham tells investors in a research note. The analyst says his feedback from key opinion leaders was "direct and unequivocal," with the leaders predicting "robust uptake" of both Zolgensma and risdiplam given signs of improved efficacy. This was at the expense of Spinraza driven by the clinical burden of intrathecal injections, says Meacham. On the basis of this feedback, he lowered his longer-term Spinraza outlook by ~$150M per year. The analyst now forecasts sales of $2.0B in 2019, declining to $1.7B in 2023. He keeps an Equal Weight rating on Biogen.
05/23/19
RBCM
05/23/19
NO CHANGE
Target $143
RBCM
Outperform
RBC sees 'interesting parallels' between Intercept and Roche-acquired InterMune
RBC Capital analyst Brian Abrahams said in a new note to investors that he sees "a number of interesting parallels" between Intercept (ICPT) and InterMune, which he notes was acquired by Roche (RHHBY) for $8.3B in 2014. While he admits that "it is not a perfect apples-to-apples comparison," he highlights that both companies' lead drugs had tolerability questions and finite exclusivity periods and that competitive risks have been "overly hyped" for Intercept's obeticholic acid and InterMune's Esbriet. The analyst, who contends that the similarities "further highlight the significant valuation disconnect" for Intercept, keeps an Outperform rating and $143 price target on the shares.
05/30/19
GUGG
05/30/19
NO CHANGE
GUGG
Buy
Array BioPharma could be seen as target after 'de-risking' data, says Guggenheim
Guggenheim analyst Michael Schmidt said Array Biopharma (ARRY) may be perceived by investors as a theoretical acquisition target following the disclosure of Phase 3 interim results of Braftovi/Mektovi in BRAF+ colorectal cancer, which he views as positive and a "de-risking event." 67% of announced acquisitions in oncology with a comparable market cap to Array had what he would consider major pipeline de-risking events in the 6 months prior to their deal announcements, Schmidt tells investors. Merck (MRK) and Pfizer (PFE) "seem to have most bandwidth for a deal," said Schmidt, who added that those two along with Bristol-Myers (BMY), AstraZeneca (AZN) and Roche (RHHBY) scored highest as possible large cap theoretical acquirers of Array in his analysis. Schmidt raised his price target on Array Biopharma shares to $38 from $37, though his analysis suggests a potential $40-$50 acquisition price if the company were to be bought.

TODAY'S FREE FLY STORIES

CARA

Cara Therapeutics

$19.13

0.29 (1.54%)

11:22
10/14/19
10/14
11:22
10/14/19
11:22
Recommendations
Cara Therapeutics analyst commentary  »

Stifel still optimistic…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AZUL

Azul

$37.10

0.25 (0.68%)

, UAL

United Airlines

$86.50

-0.68 (-0.78%)

11:20
10/14/19
10/14
11:20
10/14/19
11:20
Periodicals
Azul in talks to join United, Copa, Avianca partnership, Reuters reports »

Brazilian airline Azul…

AZUL

Azul

$37.10

0.25 (0.68%)

UAL

United Airlines

$86.50

-0.68 (-0.78%)

CPA

Copa Holdings

$98.68

-0.67 (-0.67%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Oct

  • 12

    Nov

  • 14

    Nov

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

11:17
10/14/19
10/14
11:17
10/14/19
11:17
Technical Analysis
NASDAQ market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

11:16
10/14/19
10/14
11:16
10/14/19
11:16
Technical Analysis
NYSE market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KEM

Kemet

$20.96

0.305 (1.48%)

11:15
10/14/19
10/14
11:15
10/14/19
11:15
Options
Kemet put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

I

Intelsat

$24.59

0.26 (1.07%)

11:05
10/14/19
10/14
11:05
10/14/19
11:05
Options
Intelsat call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DE

Deere

$169.81

-1.16 (-0.68%)

11:03
10/14/19
10/14
11:03
10/14/19
11:03
Hot Stocks
Deere to acquire Unimil, terms not disclosed »

Deere & Company has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Nov

SDC

SmileDirectClub

$10.48

-0.62 (-5.59%)

11:01
10/14/19
10/14
11:01
10/14/19
11:01
Hot Stocks
Breaking Hot Stocks news story on SmileDirectClub »

SmileDirectClub says…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

SDC

SmileDirectClub

$10.44

-0.66 (-5.95%)

11:00
10/14/19
10/14
11:00
10/14/19
11:00
Hot Stocks
SmileDirectClub says CA assembly bill 1519 creates 'unnecessary hurdles' »

SmileDirectClub issued a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

TPR

Tapestry

$24.69

-1.28 (-4.93%)

10:55
10/14/19
10/14
10:55
10/14/19
10:55
Options
Tapestry put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 07

    Nov

10:55
10/14/19
10/14
10:55
10/14/19
10:55
Conference/Events
Evercore REITs analyst to hold a luncheon »

REITs Analyst Sakwa holds…

PUBGY

Publicis

$0.00

(0.00%)

, DIS

Disney

$129.71

-0.37 (-0.28%)

10:54
10/14/19
10/14
10:54
10/14/19
10:54
Periodicals
Disney splitting $3B media business with Publicis, Omnicom, Campaign reports »

Disney (DIS) is set to…

PUBGY

Publicis

$0.00

(0.00%)

DIS

Disney

$129.71

-0.37 (-0.28%)

OMC

Omnicom

$74.82

0.17 (0.23%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Oct

  • 24

    Oct

  • 24

    Oct

  • 07

    Nov

ALXN

Alexion

$99.63

0.37 (0.37%)

10:45
10/14/19
10/14
10:45
10/14/19
10:45
Options
Alexion call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

  • 23

    Oct

WDC

Western Digital

$59.26

0.9 (1.54%)

, AAPL

Apple

$237.68

1.47 (0.62%)

10:39
10/14/19
10/14
10:39
10/14/19
10:39
On The Fly
Western Digital rises as analyst says buy on rising flash prices »

Shares of Western Digital…

WDC

Western Digital

$59.26

0.9 (1.54%)

AAPL

Apple

$237.68

1.47 (0.62%)

STX

Seagate

$53.60

-0.2 (-0.37%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Oct

  • 01

    Nov

  • 04

    Nov

  • 14

    Nov

  • 19

    Nov

  • 20

    Nov

HUM

Humana

$264.13

-2.2 (-0.83%)

10:34
10/14/19
10/14
10:34
10/14/19
10:34
Hot Stocks
Humana among five MA plans selected for Florida Medicare retirees »

Humana (HUM), which…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Nov

  • 13

    Nov

EHTH

eHealth

$54.37

-1.61 (-2.88%)

10:29
10/14/19
10/14
10:29
10/14/19
10:29
Recommendations
eHealth analyst commentary  »

eHealth churn concerns…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

BHC

Bausch Health

$20.50

-0.12 (-0.58%)

10:25
10/14/19
10/14
10:25
10/14/19
10:25
Options
Bausch Health call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Nov

GNUS

Genius Brands

$0.83

0.06 (7.79%)

10:25
10/14/19
10/14
10:25
10/14/19
10:25
Conference/Events
Genius Brands to host business news update conference call »

Conference call to be…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Oct

10:25
10/14/19
10/14
10:25
10/14/19
10:25
Conference/Events
UBS technology analyst to hold an analyst/industry conference call »

Technology Analyst…

SDC

SmileDirectClub

$10.56

-0.54 (-4.86%)

10:20
10/14/19
10/14
10:20
10/14/19
10:20
Recommendations
SmileDirectClub analyst commentary  »

SmileDirectClub may or…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

10:17
10/14/19
10/14
10:17
10/14/19
10:17
Technical Analysis
NASDAQ market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

10:16
10/14/19
10/14
10:16
10/14/19
10:16
Technical Analysis
NYSE market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WLL

Whiting Petroleum

$6.94

-0.5 (-6.72%)

10:15
10/14/19
10/14
10:15
10/14/19
10:15
Options
Whiting Petroleum put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PING

Ping Identity

$16.72

0.25 (1.52%)

, NVST

Envista

$27.55

-0.32 (-1.15%)

10:09
10/14/19
10/14
10:09
10/14/19
10:09
Initiation
Fly Intel: Top five analyst initiations »

Catch up on today's…

PING

Ping Identity

$16.72

0.25 (1.52%)

NVST

Envista

$27.55

-0.32 (-1.15%)

DDOG

Datadog

$36.25

0.58 (1.63%)

BYND

Beyond Meat

$125.99

-5.41 (-4.12%)

BE

Bloom Energy

$3.11

-0.055 (-1.74%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

  • 19

    Nov

  • 04

    Dec

FAST

Fastenal

$35.95

-0.41 (-1.13%)

, AMCX

AMC Networks

$46.77

-1.65 (-3.41%)

10:09
10/14/19
10/14
10:09
10/14/19
10:09
Downgrade
Fly Intel: Top five analyst downgrades »

Catch up on today's…

FAST

Fastenal

$35.95

-0.41 (-1.13%)

AMCX

AMC Networks

$46.77

-1.65 (-3.41%)

DAL

Delta Air Lines

$52.44

-0.5 (-0.94%)

TOL

Toll Brothers

$39.32

-0.17 (-0.43%)

CGC

Canopy Growth

$18.66

-0.76 (-3.91%)

HEXO

Hexo

$2.38

-0.155 (-6.11%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 24

    Oct

  • 31

    Oct

  • 12

    Nov

  • 12

    Nov

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.